



For Immediate Release

January 31, 2022

Acuitas Announces Sponsorship for the 2022 Greater Vancouver Regional Science Fair

Vancouver, B.C. – Acuitas Therapeutics is excited to announce that it has entered into a sponsorship agreement with the 2022 Greater Vancouver Regional Science Fair (GVRSF). This is a partner-level sponsorship and is concentrated on encouraging young minds to get involved in science.

Said Dr. Thomas Madden, President & CEO of Acuitas: “Contributing to the science community is very important to the Acuitas team. We know that science fairs, such as the GVRSF, help young scientists to become creative problem solvers and critical thinkers – and I think that the world needs more of that.” He added: “We are thrilled to be a part of this great event and look forward to seeing what the next generation of scientists come up with!”

“Science fairs are often students’ first exposure to what real science is about. Participation in science fairs directly influenced my own career choices and now I often employ students who have that background experience,” said Dr. Leonard Foster, Ph.D., UBC Professor and Chief Judge of the GVRSF. He continued, “Exposing young people to science through these fairs is an investment in our young people that ensures we have the skilled workforce needed to compete in the global arena. It is an investment in the future of our province.”

About the Greater Vancouver Regional Science Fair Society

The Greater Vancouver Regional Science Fair Society (www.gvrsf.ca), a non-profit charitable organization, supports students and the science fair goals of encouraging science involvement and attitudes, effort and rigor on an independent or shared project, and development of communication skills.

About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to



address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY[®], which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.

-END-